RxDoctor Payments Data

Jarrod Frydman, DO

Family Medicine · Plantation, FLNPI 1013957356

Payments from drug & device makers

$9,107in general payments, 2019–2025

Across 517 payments — averaging $17.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • GSK$812
  • AstraZeneca$769
  • Boehringer Ingelheim$677
  • Pfizer$630
  • AbbVie$481
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$9,101100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,107 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$43,049
Medicare patients
209
Services billed
488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban157$149,843
JardianceEmpagliflozin80$81,545
FarxigaDapagliflozin Propanediol66$69,443
XareltoRivaroxaban49$55,857
JanuviaSitagliptin Phosphate36$40,637
OzempicSemaglutide33$37,933
JanumetSitagliptin Phos/Metformin Hcl23$33,953
EntrestoSacubitril/Valsartan38$33,475
TrulicityDulaglutide15$24,450
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$23,632
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$19,159
LinzessLinaclotide11$16,238
TradjentaLinagliptin12$10,950
Fluticasone-SalmeterolFluticasone Propion/Salmeterol51$9,170
VascepaIcosapent Ethyl12$9,134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$630$149,843157 claims
Boehringer IngelheimJardiance, Tradjenta$677$92,49592 claims
AstraZenecaFarxiga, Breztri Aerosphere$769$88,60294 claims
MerckJanuvia, Janumet$422$74,59059 claims
Johnson & JohnsonXarelto, Invokana$269$63,16361 claims
Novo NordiskOzempic$1,611$37,93333 claims
NovartisEntresto$67$33,47538 claims
GSKTrelegy Ellipta, Anoro Ellipta$812$32,05350 claims
Lilly USA, LLCTrulicity$441$24,45015 claims
AbbVieLinzess, Synthroid$481$21,63065 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Plantation

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →